The German pharmaceuticals and agriculture giant has engineered a two-pronged strategy to ease the financial and legal pressure that has weighed on its shares for years. On Friday, Bayer announced a €3 billion deal with Apollo Global Management, giving the asset manager a minority stake in a newly created entity housing its reversible long-acting contraceptive (LARC) business. The company retains operational control and will continue to consolidate the unit fully, with the transaction expected to close in the third quarter pending antitrust approval.
This cash injection arrives at a moment when bond maturities and mounting litigation costs are straining liquidity. CEO Bill Anderson has made clear the capital is intended to keep Bayer’s long-term strategy on track without mid-course corrections.
Parallel to the Apollo announcement, Bayer filed a motion to dismiss roughly 4,000 consolidated glyphosate lawsuits pending at the federal level. The motion follows the U.S. Supreme Court’s ruling in Monsanto v. Durnell, which Bayer interprets as a fundamental shift in the legal landscape. However, presiding Judge Chhabria in San Francisco pushed back a scheduled status conference, calling initial filings from both sides “unsatisfactory” and demanding more detailed briefs. A decision remains pending.
The stock closed Friday at €50.18, down 1.03% on the day and 5.39% for the week. Yet the longer-term picture tells a different story: the shares have surged 80.99% over the past twelve months, with a 42.6% monthly gain and a 31.97% year-to-date advance. The recent rally peaked at €53.86 on July 3, a fresh 52-week high, leaving the stock about 6.8% below that level.
Technical indicators now flash caution. The 14-day relative strength index sits at 70.4, squarely in overbought territory. More strikingly, the share price trades 24.95% above its 50-day moving average and 33.18% above the 200-day average—gaps that historical patterns suggest rarely persist. The 30-day annualized volatility of 61.88% is unusually elevated for a Dax heavyweight, underscoring the market’s lingering uncertainty over legal outcomes.
Should investors sell immediately? Or is it worth buying Bayer?
Beyond the federal cases, Bayer faces more than 60,000 state-level Roundup suits. It has proposed a $7.25 billion global settlement to resolve those claims, and Judge Boyer of the Missouri Circuit Court has set a final approval hearing for August 19. A favorable ruling would eliminate the bulk of outstanding state litigation, potentially shifting investor attention back to Bayer’s operational performance.
Before that hearing, Bayer will release its second-quarter results on August 7. The earnings report will offer the first concrete look at whether the legal tailwinds are translating into improved cash flow and debt metrics. Analysts view it as a critical test of whether the share price rally rests on a solid fundamental foundation.
The bull case hinges on the Supreme Court ruling continuing to narrow the scope of glyphosate claims, allowing Bayer to win dismissal of the federal cases and secure approval of the Missouri settlement. The bear case warns that the ruling’s impact remains contested—plaintiffs’ attorney Robin Greenwald argues it only addresses product labeling, leaving other claims intact—and that the stock’s technical overextension leaves it vulnerable to sharp reversals on any negative news.
For now, Bayer has placed two large bets: one on Apollo’s willingness to inject capital into its contraceptive franchise, and another on the courts’ willingness to grant it a broad legal reprieve. August’s calendar—earnings on the 7th, the Missouri hearing on the 19th, and Judge Chhabria’s eventual decision—will determine whether those bets pay off or if the technical warnings prove prescient.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from July 12 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from July 12.
Bayer: Buy or sell? Read more here...
